Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Thank you for registering! Take a moment to confirm your subscription to Insider Trades Newsletter so that you can access MarketBeat's tools, reports, and news. Please click the "Send Confirmation Email" button and we'll send you an email with confirmation instructions.

Maximus (NYSE:MMS) Updates FY 2024 Earnings Guidance

Maximus (NYSE:MMS - Get Free Report) updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share guidance of 5.650-5.850 for the period, compared to the consensus earnings per share estimate of 4.290. The company issued revenue guidance of $5.2 billion-$5.3 billion, compared to the consensus revenue estimate of $5.2 billion. Maximus also updated its FY24 guidance to $5.65-5.85 EPS.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Maximus from a hold rating to a buy rating in a research report on Thursday, February 8th.

Get Our Latest Research Report on Maximus

Maximus Price Performance

MMS stock traded down $0.13 during midday trading on Wednesday, reaching $84.12. The stock had a trading volume of 432,989 shares, compared to its average volume of 324,740. Maximus has a 52-week low of $72.39 and a 52-week high of $89.69. The company has a market cap of $5.13 billion, a price-to-earnings ratio of 27.85 and a beta of 0.72. The company's fifty day simple moving average is $82.33 and its 200 day simple moving average is $81.61. The company has a current ratio of 1.69, a quick ratio of 1.69 and a debt-to-equity ratio of 0.71.


Maximus (NYSE:MMS - Get Free Report) last issued its earnings results on Wednesday, February 7th. The health services provider reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.06. Maximus had a return on equity of 15.68% and a net margin of 3.73%. The business had revenue of $1.33 billion for the quarter, compared to analysts' expectations of $1.29 billion. During the same period in the previous year, the firm posted $0.94 EPS. The business's revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, sell-side analysts predict that Maximus will post 5.42 earnings per share for the current fiscal year.

Maximus Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 31st. Stockholders of record on Wednesday, May 15th will be paid a $0.30 dividend. The ex-dividend date is Tuesday, May 14th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 1.43%. Maximus's payout ratio is presently 39.74%.

Insider Buying and Selling at Maximus

In other Maximus news, CFO David Mutryn sold 8,000 shares of the stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $83.95, for a total transaction of $671,600.00. Following the sale, the chief financial officer now directly owns 5,124 shares in the company, valued at approximately $430,159.80. The transaction was disclosed in a document filed with the SEC, which is available through this link. 1.40% of the stock is currently owned by corporate insiders.

Maximus Company Profile

(Get Free Report)

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.

Read More

Earnings History and Estimates for Maximus (NYSE:MMS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ Does this make you sick? (From Allegiance Gold) (Ad)

Should you invest $1,000 in Maximus right now?

Before you consider Maximus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maximus wasn't on the list.

While Maximus currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Featured Articles and Offers

Search Headlines: